US SEC Trading Suspension Halt Orders — March 17, 2026
Nasdaq listing compliance challenges dominate the USA Trading Suspensions stream, with Urgent.ly Inc. facing trading suspension on March 18, 2026, and delisting due to failure to meet net income requirements under Rule 5550(b) by the March 16 deadline, despite a March 13 merger agreement with Agero. Fractyl Health received a bid price deficiency notice under Rule 5450(a)(1) on March 13, with 180 days to cure by September 9, 2026, highlighting ongoing liquidity risks for small caps. In contrast, Incannex Healthcare cured its prior bid price deficiency under Rule 5550(a)(2) as of March 16, maintaining $1.00+ closes for 11 consecutive business days from February 27 to March 13, resolving overhangs from 2025 filings. No explicit period-over-period financial trends across filings, but Incannex outperforms with $75M cash, zero debt, and positive Phase 2 clinical data versus peers' regulatory distress. Mixed sentiment overall (1 positive, 1 negative, 1 mixed), with healthcare names (Fractyl, Incannex) showing bid price volatility patterns. Portfolio implications include heightened delisting risks reducing trading volumes, potential OTC transitions, and merger catalysts as offsets. Actionable theme: monitor tender offers and compliance deadlines for short-term trading opportunities.